Neuropsychiatric Outcomes After Mefloquine Exposure Among U.S. Military Service Members.

Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ (1996) 4.18

Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis (2001) 3.43

The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health (2002) 2.92

Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ (2003) 2.87

Drugs for preventing malaria in travellers. Cochrane Database Syst Rev (2009) 2.29

Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands. J Clin Psychiatry (2005) 1.72

User Acceptability Patterns for Mefloquine and Doxycycline Malaria Chemoprophylaxis. J Travel Med (1996) 1.52

The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J (2010) 1.42

Compliance with antimalaria chemoprophylaxis in a combat zone. Am J Trop Med Hyg (2012) 1.19

Mefloquine and doxycycline malaria prophylaxis in Australian soldiers in East Timor. Med J Aust (2005) 1.08

Mental disorders and mental health problems, active component, U.S. Armed Forces, 2000-2011. MSMR (2012) 0.96

Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol (2002) 0.94

Acute and long-term psychiatric side effects of mefloquine: a follow-up on Danish adverse event reports. Travel Med Infect Dis (2014) 0.94

Role of US military research programs in the development of US Food and Drug Administration--approved antimalarial drugs. Clin Infect Dis (2006) 0.93

The efficacy and tolerability of doxycycline and mefloquine in malaria prophylaxis of the ISAF troops in Afghanistan. J Infect (2005) 0.93

Pre-travel health, immunization status, and demographics of travel to the developing world for individuals visiting a travel medicine service. Am J Trop Med Hyg (1991) 0.92

Mefloquine use and hospitalizations among US service members, 2002-2004. Am J Trop Med Hyg (2006) 0.92

Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol (2004) 0.91

Safety, Tolerability, and Compliance with Long-Term Antimalarial Chemoprophylaxis in American Soldiers in Afghanistan. Am J Trop Med Hyg (2015) 0.89

Self-reported adverse events associated with antimalarial chemoprophylaxis in peace corps volunteers. Am J Prev Med (2007) 0.88

Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan. Malar J (2008) 0.87

Severe neuropsychiatric reaction in a deployed military member after prophylactic mefloquine. Case Rep Psychiatry (2011) 0.86

Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am J Trop Med Hyg (1996) 0.85

Malaria chemoprophylaxis regimens: a descriptive drug utilization study. Travel Med Infect Dis (2014) 0.84

Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther (2002) 0.84

Antimalarial chemoprophylaxis and the risk of neuropsychiatric disorders. Travel Med Infect Dis (2013) 0.80

Surveillance snapshot: self-reported malaria prophylaxis compliance among U.S. service members with diagnosed malaria, 2008-2013. MSMR (2014) 0.78

Malaria and mefloquine prophylaxis use among Japan Ground Self-Defense Force personnel deployed in East Timor. J Travel Med (2007) 0.78

Signal detection to identify serious adverse events (neuropsychiatric events) in travelers taking mefloquine for chemoprophylaxis of malaria. Drug Healthc Patient Saf (2012) 0.77